A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

BACKGROUND: Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidylinositol 3-kinase inhibitor, used in combination with ima...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantaleo, Maria A., Heinrich, Michael C., Italiano, Antoine, Valverde, Claudia, Schöffski, Patrick, Grignani, Giovanni, Reyners, Anna K. L., Bauer, Sebastian, Reichardt, Peter, Stark, Daniel, Berhanu, Ghimja, Brandt, Ulrike, Stefanelli, Tommaso, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078016/
https://www.ncbi.nlm.nih.gov/pubmed/35524239
http://dx.doi.org/10.1186/s12885-022-09610-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078016/
https://www.ncbi.nlm.nih.gov/pubmed/35524239
http://dx.doi.org/10.1186/s12885-022-09610-4

Ejemplares similares